This paper is only available as a PDF. To read, Please Download here.
Lymphodepletion, reconstitution and active-specific tumour cell vaccination (LRAST) enhances the tumour-specific immune response in a murine melanoma model. Myeloid derived suppressor cells (MDSC, Gr-1+ CD11b+) may decrease the induction of T-cells and their therapeutic efficacy. Aim of the study was to evaluate the benefit of MDSC depletion in addition to LRAST, using anti-Gr-1 antibody (Ab). The Gr-1 epitope is also expressed on CD8+ T-cells.
Female C57BL/6 mice with subcutaneous (s.c.) D5 melanoma were lymphodepleted with cyclophosphamide and reconstituted with naïve splenocytes. Vaccination was performed with irradiated syngeneic mGM-CSF-producing D5G6 melanoma cells. For MDSC depletion, anti-Gr-1 Ab (clone RB6-8C5, 230 μg) was injected every other day starting on the day of lymphodepletion. Induction of tumour-specific T-cells in tumour vaccine draining lymph nodes was evaluated using interferon (IFN)-γ assays. Immune cells were analysed by flow cytometry. D5 tumour growth was monitored.
Anti-Gr-1 administration had no long-lasting effect on MDSC elimination. The antibody also bound to CD8+ Gr-1+ CD44+ T memory cells. The combination of anti-Gr-1 treatment and LRAST enhanced tumour-specific IFN-γ release. Nevertheless, this did not translate into improved survival.
Given an insufficient elimination of MDSC and the possible depletion of Gr-1+ memory T-cells, the use of anti-Gr-1 Ab in our tumour model seems questionable.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect